

PRESS RELEASE

Haupt Pharma Wülfing modernizes the building for pharmaceutical development

- **Haupt Pharma Wülfing GmbH, member of the Aenova Group, resumes operations in a modernized development building.**
- **Highly specialized pharmaceutical development according to GMP regulations.**

Gronau, July 2020 - Quality and safety are the central issues in pharmaceutical development and production. This also applies, of course, to buildings and their infrastructure. Haupt Pharma Wülfing GmbH, a member of the Aenova Group with more than 4,300 employees worldwide and about 450 employees in Gronau, has now put the modernized development building back into operation.

The development area of Haupt Pharma Wülfing on Bethelner Landstraße covers around 1,000 square metres with laboratories and small-scale pharmaceutical production, various storage, air conditioning and building services, hygiene locks, washrooms and more. Here, as in the entire pharmaceutical production, many different legal requirements must be observed for reasons of product and patient safety. This also applies to the buildings and their infrastructure. Compliance with these regulatory guidelines is regularly checked and audited by the supervisory authority in Hanover.

"The development of pharmaceuticals is subject to even more specific requirements", explains Daniel Kaftan, Head of Development at Haupt Pharma Wülfing GmbH. "You have to think of it like this: we develop a dosage form on behalf of a customer, e.g. a tablet, and determine the optimal composition and the appropriate manufacturing process to ensure that the drug reaches the right place in the body. One of our main objectives and competences is



to use only minimal amounts of the new active pharmaceutical ingredients (API) during the development phase, since these are usually only available in small quantities", Kaftan continues. One of the important tasks is to produce so-called clinical trial samples for the client companies, which can be used to start the different phases of clinical trials within the very complex drug approval process.

"Pharmaceuticals are highly specialized products. The right active ingredient in the right dosage form must be found, produced and tested in order to guarantee the desired effect with lowest possible side effects and interactions with other drugs", explains Dr. Jörg Gampfer, Head of Development Services at the Aenova Group. "In the approval process, these test samples are required on a very small scale. It is therefore essential that these samples can be produced with only small quantities of a product. This requires specialized premises and equipment in pharmaceutical development," Gampfer adds. "We are very pleased that we now have the most modern infrastructure available for this. And some of the new substances evaluated there could also be relevant for COVID-19 therapy!"

"This investment is an important building block in the future of the site in Gronau. Pharmaceutical Development contributes to product renewal and acquisition of new customers and products for the Gronau production site," explains Dr. Emil Wolf, Managing Director of Haupt Pharma Wülfing GmbH.

In the last weeks of the building modernization, technical and qualitative issues were now running parallel to the resumption of operations. In a new, bright design, the building features a holistic concept with optimized surfaces, new lighting systems and partially modified utilization concepts. All equipment is now back in place and the indoor climate has been readjusted.

"The hard work of the entire team from engineering to quality assurance and development has produced a great result. So we can look forward to the next audit with confidence and are of course GMP-compliant, i.e. in line with the requirements of so-called Good Manufacturing Practice", Gampfer, Kaftan and Wolf are pleased to report.



In addition to the production of clinical study material, Haupt Pharma Wülfing GmbH also takes care of the packaging and distribution of the samples to the respective study centers for its customers. A central task of galenic development is to define the appropriate dosage form of a drug. Since this is usually done on a small scale, the manufacturing processes have to be scaled up at the end of the process so that the required quantities can be produced for the clients and hence ultimately for the patients. The company's broad portfolio also includes the development of analytical methods. In times of the COVID-19 pandemic, it is precisely these areas of activity of the pharmaceutical industry that have moved into the focus of public attention. "All this is what we in the Aenova Group offer our customers with our research and development services at the highest level", Gampfer proudly reports. "By the way, in this area we are also active in apprenticeship and train so-called pharmaceutical technicians, an exciting and promising profession", Kaftan adds.

Haupt Pharma Wülfing GmbH is a nationally and internationally active company in contract development and contract manufacturing of pharmaceutical products and dietary supplements. Special expertise exists in the development, production and packaging of tablets, suppositories and sterile liquids. Haupt Pharma Wülfing GmbH belongs to the Aenova Group, one of the leading companies in the pharmaceutical and healthcare industry worldwide.



[Caption:]

The modernized development building of Haupt Pharma Wülfing GmbH in Gronau is reopened by development manager Daniel Kaftan, project manager Sarah Bahr, the local works council chairwoman Heike Tietze and site manager Dr. Emil Wolf (from left to right)
Photo: Haupt Pharma Wülfing GmbH



[Caption:]

Preparation for the production of a test product to be developed for the treatment of Alzheimer's disease. Christoph Müller and Nicole Voß-Naujeck, both pharmaceutical development at Haupt Pharma Wülfing GmbH (from left to right). Photo: Haupt Pharma Wülfing GmbH.



The Aenova Group

The Aenova Group is one of the leading companies in the pharmaceutical and healthcare industry. With high quality standards, innovative technologies and a clear future orientation, Aenova has become the European market leader for the development and production of all common dosage forms and product groups in the business-to-business sector. The company, headquartered near Munich, operates 15 production sites and several sales offices in ten countries around the world. More than 4,300 employees contribute to the group's success.

Contact for further inquiries:

Dr. Susanne Knabe
Head of Communications & PR
Aenova Holding GmbH
Berger Straße 8-10
D-82319 Starnberg

Mobile: +49 170 22 368 42
E-mail: susanne.knabe@aenova-group.com